BACKGROUND Patients with diffuse glioma experience many tumor- and treatment-related symptoms, including fatigue, cognitive deficits, and anxiety. It remains unclear how the frequency and burden of these symptoms change over time and specifically which symptoms patients experience during the stable phase of the disease. We assessed the frequency and burden of common symptoms in glioma patients during stable disease and whether patients were willing to undergo treatment for those symptoms. We suggest a top five of potentially treatable symptoms. METHODS Patients with a diffuse glioma during stable disease completed a questionnaire on symptoms they experienced during the past two weeks, such as irritability, fatigue, stress, pain, depressive thoughts and relationship problems. They rated the frequency and burden of seventeen symptoms on a seven-point numeric scale ranging from ‘never’ to ‘continuously’ and from ‘no burden’ to ‘unbearable’, respectively. Also, they stated whether they were willing to undergo treatment for each symptom. Data was collected retrospectively. The median values of the frequency and burden dimension were calculated for each symptom. We composed a top five of most frequent and burdensome symptoms. We used Kendall’s Tau to correlate frequency, burden and willingness to undergo treatment per symptom. RESULTS Fifty-two patients were included, 77% had a KPS score of 90–100, 23% a KPS score of 70–80 and 40% had a glioblastoma. The top five most frequent and burdensome symptoms were fatigue, memory problems, reduced physical fitness, concentration problems and drowsiness. Fatigue had the highest median value on the frequency (median 4.5, IQR 2.5) and burden (median 4.0, IQR 3.00) dimension and 21% of the patients were willing to undergo treatment for fatigue. Overall 35% of the patients were willing to undergo treatment for at least one symptom. Frequency and burden of symptoms correlated well (median Kendall’s Tau of 0.84 with a range of correlations of 0.73–0.95). Frequency and willingness to undergo treatment correlated less (median Kendall’s Tau of 0.35, range 0.24–0.57), as well as burden and willingness to undergo treatment (median Kendall’s Tau, range 0.28–0.61). CONCLUSION The top five symptoms most often reported by patients with diffuse glioma during stable disease were: fatigue, memory problems, reduced physical fitness, concentration problems and drowsiness. These symptoms may serve as a roadmap for future research on treatment strategies to alleviate these symptoms. SUPPORT/DISCLOSURE This project is funded by The Anita Veldman Foundation (CCA-2019-2-21).

中文翻译：

---

P12.02 弥漫性胶质瘤患者在疾病稳定期间的症状作为潜在治疗目标

背景 弥漫性神经胶质瘤患者经历许多与肿瘤和治疗相关的症状，包括疲劳、认知缺陷和焦虑。目前尚不清楚这些症状的频率和负担如何随时间变化，特别是患者在疾病稳定阶段会经历哪些症状。我们评估了稳定期胶质瘤患者常见症状的频率和负担，以及患者是否愿意接受这些症状的治疗。我们建议前五名可能治疗的症状。方法 弥漫性胶质瘤患者在疾病稳定期间完成了一份关于他们在过去两周内经历的症状的问卷调查，例如易怒、疲劳、压力、疼痛、抑郁想法和人际关系问题。他们分别以从“从不”到“持续”和从“无负担”到“难以忍受”的七点数字量表对 17 种症状的频率和负担进行了评分。此外，他们还说明了他们是否愿意为每种症状接受治疗。数据是回顾性收集的。计算每个症状的频率和负担维度的中值。我们将最常见和最繁重的症状排在前五名。我们使用 Kendall 的 Tau 来关联频率、负担和每个症状接受治疗的意愿。结果 共纳入 52 名患者，77% 的 KPS 评分为 90-100，23% 的 KPS 评分为 70-80，40% 的患者患有胶质母细胞瘤。前五名最常见和最繁重的症状是疲劳、记忆力问题、体能下降、注意力不集中和嗜睡。疲劳在频率（中位数 4.5，IQR 2.5）和负担（中位数 4.0，IQR 3.00）维度上的中值最高，21% 的患者愿意接受疲劳治疗。总体而言，35% 的患者愿意接受至少一种症状的治疗。症状的频率和负担相关性很好（Kendall's Tau 中位数为 0.84，相关范围为 0.73-0.95）。接受治疗的频率和意愿相关性较小（中位数 Kendall's Tau 为 0.35，范围 0.24-0.57），以及接受治疗的负担和意愿（中位数 Kendall's Tau，范围 0.28-0.61）。结论 弥漫性胶质瘤患者在疾病稳定期间最常报告的前五种症状是：疲劳、记忆力问题、体能下降、注意力不集中和嗜睡。这些症状可以作为未来研究缓解这些症状的治疗策略的路线图。支持/披露 该项目由 Anita Veldman 基金会 (CCA-2019-2-21) 资助。